Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese API Maker Huahai Leaps Into IO Via Korean Startup

Executive Summary

A frenzy for innovation has more Chinese companies armed with cash shopping for new assets. Huahai is the latest to jump onboard the increasingly competitive immuno-oncology field.

You may also be interested in...



Korea Stepping Up IO R&D To Catch Up With Global Players, Trends

Immuno-oncology deals and R&D by South Korean companies are picking up speed as they are put more focus on the hot sector in line with global trends.

What's Driving The Uptick In Korea-China Biotech Deals

Bilateral ties between South Korea and China may have slumped to a new low, but that doesn’t seem to have deterred deals between firms in the two nations in the biotech space. Scrip takes a closer look at the deal-making flow and whether it is sustainable.

After Record Series A, Eutilex Eyes T-Cell, Antibody Partnerships

Although established only last year, Eutilex is rapidly making its way in the immuno-oncology space. After closing one of the biggest ever Series A funding rounds by a South Korean bioventure, its CEO talks to Scrip about next steps and the priorities for next year.

Topics

Related Companies

UsernamePublicRestriction

Register

MT125711

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel